Journal ArticleDOI
Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients
Reads0
Chats0
TLDR
The unstable status for ER or HER2 in breast cancer seems to be clinically significant and to correlate with a worse prognosis, and an evident change in ER, PR and HER2 between breast primary tumors and relapsing tumors is shown.Abstract:
The aim of this study was to evaluate the frequency and prognostic impact of changes in the estrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2) status between primary and recurrent/metastatic lesions (RML). We investigated 133 breast cancer patients for ER, PR and HER2 status of primary and RML and their follow-up records. Among 133 patients with RML, discordance rate for ER, PR, and HER2 was 18.8, 33.8, and 6.8%, respectively. ER, PR and HER2 discordance were observed in 20.0, 38.1 and 6.7% of the patients with distant metastasis, and in 14.3, 17.9 and 7.1% of the patients with locoregional recurrence. The mean time between the primary diagnosis and last contact or death was 57 (range 22-78) months and between the recurrence biopsy and last contact or death was 17 (range 1-33) months. Among 133 patients with RML, the ER-discordant cases and ER-loss cases experienced a worse overall survival (OS) (p=0.001 and p=0.016, respectively) and post-recurrence survival (PRS) (p=0.001 and p=0.018, respectively), compared with the respective concordant cases. The HER2-discordant patients and HER2-loss patients had a poorer OS (p=0.008 and p=0.001, respectively) and PRS (p=0.004 and p=0.000, respectively) than the respective concordant cases. Among 105 patients with distant metastasis, ER discordance, ER loss, HER2 discordance and HER2 loss, compared with the respective concordant cases, resulted in a worse OS and PRS (p<0.05 for all). Our findings show an evident change in ER, PR and HER2 between breast primary tumors and relapsing tumors. The unstable status for ER or HER2 in breast cancer seems to be clinically significant and to correlate with a worse prognosis.read more
Citations
More filters
Journal ArticleDOI
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Suzanne E. Wardell,Matthew J. Ellis,Holly M. Alley,Koleen Eisele,Todd VanArsdale,Stephen Dann,Kim Arndt,Tina Primeau,Elizabeth Griffin,Jieya Shao,Robert J. Crowder,Jin-Ping Lai,John D. Norris,Donald P. McDonnell,Shunqiang Li +14 more
TL;DR: A new class of selective estrogen receptor modulators (SERM)/SERD hybrids (SSH) that downregulate ESR1 in relevant models of endocrine-resistant breast cancer have therapeutic potential in breast tumors resistant to endocrine therapies or those expressing ESR 1 mutations.
Journal ArticleDOI
Transcriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival
Wenna Guo,Qiang Wang,Yueping Zhan,Xijia Chen,Qi Yu,Jiawei Zhang,Yi Wang,Xin-Jian Xu,Liucun Zhu +8 more
TL;DR: Results suggested that RNA-seq transcriptome profiling provides that the three-lncRNA signature is an independent prognostic biomarker, and have clinical significance, and lncRNA, miRNA, and mRNA interaction network indicated lncRNAs may intervene in breast cancer pathogenesis by binding to miR-190b, acting as competing endogenous RNAs.
Journal ArticleDOI
Immuno-PET for Clinical Theranostic Approaches
Clément Bailly,Pierre-François Cléry,Alain Faivre-Chauvet,Mickaël Bourgeois,Mickaël Bourgeois,François Guérard,Ferid Haddad,Jacques Barbet,Michel Chérel,Françoise Kraeber-Bodéré,Thomas Carlier,Caroline Bodet-Milin +11 more
TL;DR: Monoclonal antibodies labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution.
Journal ArticleDOI
Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Renu Gahlaut,Aneliese Bennett,H. Fatayer,Barbara J. Dall,Nisha Sharma,Galina Velikova,Timothy J. Perren,David Dodwell,Mark Lansdown,Abeer M Shaaban +9 more
TL;DR: Significant changes in tumour morphology, grade, hormone receptors and HER2 status occur following NACT and it is recommended that testing on residual invasive carcinoma be repeated on residual tumours.
Journal ArticleDOI
Molecular Concordance Between Primary Breast Cancer and Matched Metastases
Anne Bruun Krøigård,Anne Bruun Krøigård,Martin Jakob Larsen,Martin Jakob Larsen,Mads Thomassen,Mads Thomassen,Torben A Kruse,Torben A Kruse +7 more
TL;DR: In conclusion, biopsy of metastatic lesions at recurrence of breast cancer is encouraged to provide optimal treatment of the disease and has the potential to identify novel, potentially druggable, drivers of progression.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.